¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Abnormal results of other endocrine function studies"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • articulatory function
    ¹ß¼º±â´É, ±¸À½±â´É
  • autonomous function
    ÀÚÀ²±â´É
  • compensatory function
    º¸»ó±â´É
  • conceptual function
    °³³ä±â´É
  • cardiac function curve
    ½ÉÀå±â´É°î¼±
  • cumulative distribution function
    ´©ÀûºÐÆ÷ÇÔ¼ö
  • discriminative sensory function
    ½Äº°°¨°¢±â´É
  • executant ego function
    ÁýÇàÀھƱâ´É
  • feeling function
    °¨Á¤±â´É
  • function
    1. ±â´É 2. ÀÛ¿ë 3. ÇÔ¼ö
  • function distribution
    ÇÔ¼öºÐÆ÷
  • holding function
    ÁöÁö±â´É
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal involuntary movement scale
    ºñÁ¤»óºÒ¼öÀǿôµµ
  • abnormal retinal correspondence
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • articulatory function
    ¹ß¼º±â´É, ±¸À½±â´É
  • autonomous function
    ÀÚÀ²±â´É
  • visuoperceptual function assessment
    ½Ã°¢Áö°¢±â´ÉÆò°¡
  • bone marrow function test
    °ñ¼ö±â´É°Ë»ç
  • brain function mapping
    ³ú±â´ÉÁöµµÈ­
  • cardiac function curve
    ½ÉÀå±â´É°î¼±
  • compensatory function
    º¸»ó±â´É
  • conceptual function
    °³³ä±â´É
  • cumulative distribution function
    ´©ÀûºÐÆ÷ÇÔ¼ö
  • discriminative sensory function
    ½Äº°°¨°¢±â´É
  • function distribution
    ºÐÆ÷ÇÔ¼ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • SOS function
    SOS[¼Õ»óº¹±¸]±â´É
  • adrenocortical function
    ºÎ½ÅÇÇÁú±â´É.
  • algebraic function
    ´ë¼öÇÔ¼ö.
  • function key
    ±â´É Ű
  • gastric function test
    À§±â´É°Ë»ç.
  • gustatory function
    ¹Ì°¢±â´É
  • hearing function
    û°¢±â´É
  • hemoglobin synthesis/function
    Ç÷»ö¼ÒÇÕ¼º/±â´É
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abnormal reflex
    ÀÌ»ó¹Ý»ç(~ÚãÞÒ).
  • abnormal retinal correspondance
    ÀÌ»ó¸Á¸·´ëÀÀ
  • abnormal shape
    ÀÌ»óÇüÅÂ
  • abnormal temperature
    ÀÌ»ó¿Âµµ, ÀÌ»óü¿Â(~ü¿Â).
  • abnormal uterine bleeding
    ÀÌ»óÀÚ±ÃÃâÇ÷(~í­Ïàõóúì).
  • abocclusion =abnormal occlusion
    °³±³(ËÒÎá).
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • subtotal abnormal shape
    ºÎºÐÀÌ»óÇüÅÂ
  • total abnormal shape
    ÀüüÀÌ»óÇüÅÂ
  • cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ¼±Á¾ ÁõÈıº(ÝÂìÆàõÒýÛ¡Ò®ÝÂù²àÍðþñøý¦ÏØ).
  • endocrine
    ³»ºÐºñ(Ò®ÝÂÝô)
  • endocrine cataract
    ³»ºÐºñ¼º¹é³»Àå
  • endocrine cell
    ³»ºÐºñ ¼¼Æ÷(Ò®ÝÂÝô á¬øà)
  • endocrine cell
    ³»ºÐºñ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ALFT abnormal liver function test
PNP pancreatic polypeptide; para-nitrophenol; peak negative pressure; pediatric nurse practitioner; peri...
PVP penicillin V potassium; peripheral vein plasma; peripheral venous pressure; polyvinylpyrrolidone; po...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
SEER Surveillance Epidemiology and End Results [Program]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AUB Abnormal Uterine Bleeding
Awd Abnormal wing disc
TAM Transient abnormal myelopoiesis
DRO Differential Reinforcement of Other Behaviour
MOTT Mycobacteria Other Than Tuberculosis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • abnormal child
    ºñÁ¤»ó¾Æ
    Çüųª ±â´ÉÀûÀ¸·Î Á¤»óÀ» ¹þ¾î³­ ¾ÆÀÌ.
  • abnormal cusp
    ÀÌ»ó ±³µÎ, ºñÁ¤»ó ±³µÎ, ÀÌ»ó Ä¡¾Æ °áÀý
    µ¿ÀǾî=abnormal tubercle. ÀÌ»óÇÑ ÇüÅÂÀÇ Ä¡¾Æ °áÀý. Ä¡¾Æ¿¡ ÀÖ´Â ±³µÎÀÇ ¼ö³ª ÇüŰ¡ ºñÁ¤»óÀûÀÎ »óÅÂ.
  • abnormal eruption
    ºñÁ¤»ó ¸ÍÃâ
    À¯Ä¡³ª ¿µ±¸Ä¡¿¡ À־ Áö³ªÄ¡°Ô ºü¸£°Å³ª ´Ê°Ô ¸ÍÃâÇÏ´Â Çö»ó.
  • abnormal fetal presentation
    ÀÌ»ó ÅÂÀ§
    žÆÀÇ À§Ä¡°¡ ºñÁ¤»óÀûÀÎ °Í.
  • abnormal frenum
    ÀÌ»ó °è´ë, °è´ë ÀÌ»ó
    Á¤»óÀÌ ¾Æ´Ñ °è´ë, ¼Ò´ë. ¼Ò´ë°¡ Á¤»óº¸´Ù ª°Å³ª ±æ ¼ö ÀÖÀ¸¸ç, ±¸¼ø ¼Ò´ëÀÎ °æ¿ì¿¡´Â 1°³ ÀÌ»óÀÏ ¼öµµ ÀÖ´Ù.
  • abnormal fusion
    ºñÁ¤»ó À¶ÇÕ
    ¹ß»ý ½Ã Á¶Á÷ÀÌ Á¤»óÀûÀ¸·Î ÇÕÃÄÁöÁö ¸øÇÏ´Â »óÅÂ. ´ëºÎºÐ Á¤Áߺο¡ °á¼ÕÀ» ³ªÅ¸³½´Ù.
  • abnormal growth
    ºñÁ¤»ó ¼ºÀå
    ¼ºÀåÀÌ Á¤»óÀûÀÎ ¹üÀ§¸¦ ¹þ¾î³­ »óÅÂ. Á¤»óº¸´Ù »¡¸® ÀÚ¶ö ¼öµµ ÀÖ°í ´Ê°Ô ÀÚ¶ö ¼öµµ ÀÖ´Ù.
  • abnormal jaw closure
    ÀÌ»ó ¾Ç°ñ ±³ÇÕ, ¾Ç°ñ ±³ÇÕ ÀÌ»ó
    ¼Ò±¸Ä¡¿Í ´ë±¸Ä¡ÀÇ ±³ÇÕ¸éÀ̳ª ¹Ý´ëÆí ±³ÇÕ¸éÀÇ Á¢ÃËÀÌ Á¤»óÀ» ¹þ¾î³ª´Â °æ¿ì.
  • abnormal laterality syndrome
    ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıº
    ½ÉÀå¿¡¼­ Á¤»óÀûÀÎ ÁÂ¿ì ´ëĪÀÌ µÚ¹Ù²î°Å³ª ºÒ¿ÏÀüÇÑ °æ¿ì·Î¼­, ÁÂÃøÀ̳ª ¿ìÃøÇüÀ¸·Î ´ëĪÀÎ °æ¿ì°¡ ÀÖ°í À̵鿡¼­ ¿©·¯ °¡Áö ½ÉÀå ±âÇüÀÌ µ¿¹ÝµÇ´Âµ¥ ÀÌ·¯ÇÑ °æ¿ì¸¦ ½ÉÀåÀÇ ÁÂ¿ì ºñ´ëĪ ÀÌ»ó ÁõÈıºÀ̶ó ÇÑ´Ù. À̵é Áúȯ¿¡¼­´Â ½ÉÀå »Ó ¾Æ´Ï¶ó ÁÖ ±â°üÁö¿Í »óÆóµ¿¸ÆÀÇ À§Ä¡ °ü°è ¹× ÆóÀÇ ºÐ¿±, °£°ú ºñÀåÀÇ ÇüÅ ¹× À§Ä¡°¡ ´Þ¶óÁö¸ç ƯÈ÷ ºñÀåÀÌ ¾ø´Â ¹«ºñÁõ
  • abnormal liquid
    ºñÁ¤»ó ¾×ü
  • abnormal movement
    ºñÁ¤»óÀû ¿îµ¿, ÀÌ»ó ¿îµ¿
    »óÇÏ¾Ç Ä¡¿­ ¹× ±³ÇÕÀÌ Á¤»óÀ» ¹þ¾î³ª ¾î±ß³­ »óÅ·ΠÇϾÇÀÌ ¿òÁ÷ÀÌ´Â °Í.
  • abnormal occlusal wear
    ºñÁ¤»ó ±³¸ð, ºñÁ¤»óÀûÀÎ ±³¸ð
    »óÇÏ¾Ç Ä¡¾ÆÀÇ ¸¶Âû·Î ÀÎÇØ ÀϾ´Â Á¤»óÀûÀÎ ±³¸ðº¸´Ù ´õ ¸¹ÀÌ ´â°Å³ª Àû°Ô ´â´Â °æ¿ì·Î¼­ ´ëºÎºÐ Á¤»óº¸´Ù ´õ ¸¹ÀÌ ´â´Â °æ¿ì¸¦ ÀǹÌÇÑ´Ù.
  • abnormal position
    À§Ä¡ ÀÌ»ó
    Á¤»óÀûÀÎ À§Ä¡¿¡¼­ ¹þ¾î³­ »óÅÂ. Á¶Á÷ÀÌ ÀÖ¾î¾ß ÇÒ À§Ä¡¿¡¼­ ¹þ¾î³­ »óÅÂ.
  • abnormal protein
    ºñÁ¤»ó ´Ü¹éÁú
  • abnormal quality
    ºñÁ¤»óÀûÀÎ ¼ºÁú
    Á¤»ó¿¡¼­ ¹þ¾î³­ ¼ºÁú.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
retrospective studies Studies used to test aetiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
(12 Dec 1998)
pharmalogical studies <pharmacology> Studies to assess the potential harmful or other effects of drugs
(16 Dec 1997)
clinical studies <pharmacology> Human studies that are designed to measure the safety, efficacy, and appropriate dosage of a new drug or biological. Clinical studies routinely involve the use of a placebo group that is given an inactive substance that looks like the test product.
(14 Nov 1997)
cohort studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesised to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
(12 Dec 1998)
combination studies <pharmacology> Studies in which a new drug is evaluated in combination with existing drugs.
(09 Jan 1998)
multicenter studies Controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children.
(12 Dec 1998)
multivariate studies The use of statistical techniques for the simultaneous investigations of the influence of several variables.
(05 Mar 2000)
preclinical studies <pharmacology> Studies in which a drug is tested on animals and in other non-human test systems. Safety information from such studies are used to support an investigational new drug application.
(14 Nov 1997)
sampling studies Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled.
(12 Dec 1998)
prospective studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
(12 Dec 1998)
his bundle studies <cardiology> This test studies the electrical activity of the bundle of HIS.
The bundle of HIS is a group of electrical fibres in the heart that are responsible for transmitting the electrical impulses which generate a normal cardiac contraction. This test may be performed in cases of cardiac arrhythmias, to locate a specific area responsible for a conduction defect and to determine the need for cardiac pacemaker placement.
The test involves the passage of a an electrode tipped catheter into the heart. This catheter is usually threaded through a neck, arm or chest vein. Measurements of the HIS bundle can then be performed while standard ECG leads are placed on the arms and legs.
This test carries a small risk of bleeding, arrhythmias, embolism, heart attack and stroke. It is performed by a specially trained cardiologist.
(27 Sep 1997)
immunofluorescent studies <technique> A special assay that relies on the production of measurable fluorescent light. An immunofluorescent tagged antibody interacts and binds with an antigen allowing an indirect measurement of its concentration.
(27 Sep 1997)
intervention studies Epidemiologic investigations designed to test a hypothesised cause-effect relation by modifying the supposed causal factor(s) in the study population.
(12 Dec 1998)
intracardiac electrophysiology studies <cardiology, investigation> A special study that involves the placement of electrodes inside the heart to map the electrical characteristics of the heart.
This study is carried out in a specially equipped lab and is similar to a cardiac catheterisation procedure. Electrodes are placed inside the heart via a catheter placed into a vein. The electrodes are positioned near the heart's conduction system and an electrical map of the heart can be determined.
This test is often performed in those where a life-threatening cardiac arrhythmia is a problem. The location and characteristics of an arrhythmia can be determined, thus guiding medical management of the problem. Patients with Wolf Parkinson White syndrome or sick sinus syndrome may have this test as part of their evaluation.
(27 Sep 1997)
organizational case studies Descriptions and evaluations of specific health care organizations.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • function
    ±â´É,¿ªÇÒ,ÀÛ¿ëÇÏ´Ù
  • continuous function
    ¿¬¼Ó °î¼± ÇÔ¼ö
  • distribution function
    (Åë°è)ºÐÆ÷ ÇÔ¼ö
  • function
    ±â´É;ÀÛ¿ë;ÀÓ¹«;ÀǽÄ;ÇÔ¼ö;ÀÛ¿ëÇÏ´Ù;Á÷ºÐÀ» ´ÙÇÏ´Ù
  • function word
    ±â´É¾î(ÀüÄ¡»ç,Á¢¼Ó»ç,Á¶µ¿»ç µî)
  • periodic function
    ÁÖ±â ÇÔ¼ö 
  • power function
    °ËÃâ·Â ÇÔ¼ö
  • probability density function
    È®·ü ¹Ðµµ ÇÔ¼ö )
  • probability function
    È®·ü ÇÔ¼ö
  • propositional function
    ¸íÁ¦ ÇÔ¼ö 9
  • rational function
    À¯¸® ÇÔ¼ö 
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á